ARTICLE | Company News
Alkermes expands CNS pipeline with Rodin acquisition
November 19, 2019 12:01 AM UTC
A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal.
The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain its profitability and signaled an interest in new business development opportunities in its core focus areas of CNS and oncology (see "Alkermes Restructures”)...